Five years in­to neoanti­gen work, cash-strapped Geno­cea lays off staff as it looks for 's­trate­gic al­ter­na­tives'

Days af­ter re­port­ing “en­cour­ag­ing” da­ta at AACR that how­ev­er failed to en­thuse in­vestors, Geno­cea Bio­sciences says it’s time to seek “strate­gic al­ter­na­tives.”

As a re­sult …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER